γ-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease

[1]  N. Belyaev,et al.  The Aβ‐clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain , 2014, Journal of neurochemistry.

[2]  V. Kemmel,et al.  Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death , 2014, Neuroscience.

[3]  Zheng Wang,et al.  Valproic Acid Reduces Neuritic Plaque Formation and Improves Learning Deficits in APPSwe/PS1A246E Transgenic Mice via Preventing the Prenatal Hypoxia‐Induced Down‐Regulation of Neprilysin , 2014, CNS neuroscience & therapeutics.

[4]  J. Fine,et al.  Intranasal administration of CNS therapeutics to awake mice. , 2013, Journal of visualized experiments : JoVE.

[5]  C. Mathis,et al.  Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice , 2013, Neurobiology of Aging.

[6]  E. Eckman,et al.  Endothelin-converting Enzymes Degrade Intracellular β-Amyloid Produced within the Endosomal/Lysosomal Pathway and Autophagosomes* , 2013, The Journal of Biological Chemistry.

[7]  N. Belyaev,et al.  The Alzheimer's Amyloid-Degrading Peptidase, Neprilysin: Can We Control It? , 2012, International journal of Alzheimer's disease.

[8]  J. Olsen,et al.  α4βδ GABAA receptors are high-affinity targets for γ-hydroxybutyric acid (GHB) , 2012, Proceedings of the National Academy of Sciences.

[9]  J. Götz,et al.  Alzheimer's Disease, Oestrogen and Mitochondria: an Ambiguous Relationship , 2012, Molecular Neurobiology.

[10]  G. Mayer.  The use of sodium oxybate to treat narcolepsy , 2012, Expert review of neurotherapeutics.

[11]  Á. Hunya,et al.  A novel method for the rapid determination of beta-amyloid toxicity on acute hippocampal slices using MTT and LDH assays , 2012, Brain Research Bulletin.

[12]  D. I. Lewis,et al.  Effect of Sodium Valproate Administration on Brain Neprilysin Expression and Memory in Rats , 2012, Journal of Molecular Neuroscience.

[13]  M. Ahamed,et al.  Protective effect of sulphoraphane against oxidative stress mediated toxicity induced by CuO nanoparticles in mouse embryonic fibroblasts BALB 3T3. , 2012, The Journal of toxicological sciences.

[14]  N. Belyaev,et al.  Are amyloid‐degrading enzymes viable therapeutic targets in Alzheimer’s disease? , 2012, Journal of neurochemistry.

[15]  S. Love,et al.  A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.

[16]  Z. Wang,et al.  Hypoxia-Induced Down-Regulation of Neprilysin by Histone Modification in Mouse Primary Cortical and Hippocampal Neurons , 2011, PloS one.

[17]  J. Hauw,et al.  Neuropathology of Sleep Disorders: A Review , 2011, Journal of neuropathology and experimental neurology.

[18]  R. Marr,et al.  Intranasal Phosphoramidon Increases Beta-Amyloid Levels in Wild-Type and NEP/NEP2-Deficient Mice , 2011, Journal of Molecular Neuroscience.

[19]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[20]  E. Capetillo-Zarate,et al.  Effects of Synaptic Modulation on β-Amyloid, Synaptophysin, and Memory Performance in Alzheimer's Disease Transgenic Mice , 2010, The Journal of Neuroscience.

[21]  R. Sircar,et al.  Effects of γ-hydroxybutyric acid on spatial learning and memory in adolescent and adult female rats , 2010, Pharmacology Biochemistry and Behavior.

[22]  M. Morris,et al.  Concentration-Effect Relationships for the Drug of Abuse γ-Hydroxybutyric Acid , 2010, Journal of Pharmacology and Experimental Therapeutics.

[23]  D. Aunis,et al.  A single acute pharmacological dose of γ-hydroxybutyrate modifies multiple gene expression patterns in rat hippocampus and frontal cortex. , 2010, Physiological genomics.

[24]  N. Belyaev,et al.  Sodium valproate: an old drug with new roles. , 2009, Trends in pharmacological sciences.

[25]  D. Aunis,et al.  Pharmacological doses of gamma-hydroxybutyrate (GHB) potentiate histone acetylation in the rat brain by histone deacetylase inhibition , 2009, Neuropharmacology.

[26]  R. Griffiths,et al.  Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers , 2009, Psychopharmacology.

[27]  J. Kapfhammer,et al.  A PKC-Dependent Recruitment of MMP-2 Controls Semaphorin-3A Growth-Promoting Effect in Cortical Dendrites , 2009, PloS one.

[28]  J. Malter,et al.  Effects of HNE‐modification induced by Aβ on neprilysin expression and activity in SH‐SY5Y cells , 2009, Journal of neurochemistry.

[29]  I. McGregor,et al.  The distribution of γ-hydroxybutyrate-induced Fos expression in rat brain: Comparison with baclofen , 2009, Neuroscience.

[30]  S. Love,et al.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. , 2009, American journal of translational research.

[31]  N. Belyaev,et al.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease , 2009, EMBO reports.

[32]  M. P. Castelli,et al.  Multi-faceted aspects of gamma-hydroxybutyric acid: a neurotransmitter, therapeutic agent and drug of abuse. , 2008, Mini reviews in medicinal chemistry.

[33]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[34]  I. Verma,et al.  Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. , 2008, The American journal of pathology.

[35]  A. Jochemsen,et al.  Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis , 2007, Cell Death and Differentiation.

[36]  N. Nalivaeva,et al.  New Insights into the Roles of Metalloproteinases in Neurodegeneration and Neuroprotection , 2007, International Review of Neurobiology.

[37]  F. Gage,et al.  Neprilysin protects neurons against Aβ peptide toxicity , 2007, Brain Research.

[38]  R. Adams,et al.  Improved sleep and neurocognitive functions in a child with thalamic lesions on sodium oxybate , 2007, Neurology.

[39]  D. Aunis,et al.  Cloning and functional characterization of a gamma‐hydroxybutyrate receptor identified in the human brain , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  G. Gessa,et al.  Gamma-Hydroxybutyrate Reduces both Withdrawal Syndrome and Hypercortisolism in Severe Abstinent Alcoholics: An Open Study vs. Diazepam , 2007, The American journal of drug and alcohol abuse.

[41]  R. Nitsch,et al.  Neuronal neprilysin overexpression is associated with attenuation of Aβ-related spatial memory deficit , 2006, Neurobiology of Disease.

[42]  S. Love,et al.  Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy , 2006, Journal of neuropathology and experimental neurology.

[43]  W. Froestl,et al.  Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons , 2005, Psychopharmacology.

[44]  G. Laviola,et al.  Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer’s disease , 2005, Behavioural Brain Research.

[45]  Takayoshi Suzuki,et al.  Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. , 2005, Journal of medicinal chemistry.

[46]  J. Montplaisir,et al.  A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. , 2004, Sleep.

[47]  T. Scammell,et al.  Pharmacotherapy for cataplexy. , 2004, Sleep medicine reviews.

[48]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[49]  D. Aunis,et al.  Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator γ‐hydroxybutyrate , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  F. Gage,et al.  Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.

[51]  T. Saido,et al.  Region‐specific reduction of Aβ‐degrading endopeptidase, neprilysin, in mouse hippocampus upon aging , 2002, Journal of neuroscience research.

[52]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Iwatsubo,et al.  Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* , 2001, The Journal of Biological Chemistry.

[54]  S. Turner,et al.  Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.

[55]  F. Lamanna,et al.  Long-Term Therapy using GHB (Sodium Gamma Hydroxybutyrate) for Treatment-Resistant Chronic Alcoholics , 2001, Journal of psychoactive drugs.

[56]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[57]  J. Cresto,et al.  Degradation of Soluble Amyloid β-Peptides 1–40, 1–42, and the Dutch Variant 1–40Q by Insulin Degrading Enzyme from Alzheimer Disease and Control Brains , 2000, Neurochemical Research.

[58]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[59]  M. Maitre.  THE γ-HYDROXYBUTYRATE SIGNALLING SYSTEM IN BRAIN: ORGANIZATION AND FUNCTIONAL IMPLICATIONS , 1997, Progress in Neurobiology.

[60]  S. Williams,et al.  Gamma-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABAB receptor-mediated hyperpolarization , 1995, Neuroscience.

[61]  M. Scharf,et al.  GHB—new hope for narcoleptics? , 1989, Biological Psychiatry.

[62]  J. Hirschowitz,et al.  The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. , 1985, The Journal of clinical psychiatry.

[63]  F. Gage,et al.  Neprilysin protects neurons against Abeta peptide toxicity. , 2007, Brain research.

[64]  Nobuhisa Iwata,et al.  Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. , 2005, Nature medicine.

[65]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[66]  L. Mucke,et al.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Maitre.  The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. , 1997, Progress in neurobiology.

[68]  L. Hersh,et al.  Neprilysin: assay methods, purification, and characterization. , 1995, Methods in enzymology.

[69]  L. Hersh,et al.  [16] Neprilysin: Assay methods, purification, and characterization , 1995 .

[70]  F. Hiller,et al.  The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. , 1990, Sleep.